Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.31
$0.40
50-Day Range
$0.33
$0.33
52-Week Range
$0.25
$1.19
Volume
4.12 million shs
Average Volume
173,401 shs
Market Capitalization
$17.03 million
P/E Ratio
N/A
Dividend Yield
123.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENZ Stock News Headlines

Battery Ventures Completes Take-Private of Enzo Biochem
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
ENZB - Enzo Biochem Inc Dividends - Morningstar
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem, Inc. (NYSE:ENZ) announced its earnings results on Monday, March, 17th. The medical research company reported ($0.02) EPS for the quarter. The medical research company had revenue of $7.33 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 7.96% and a negative net margin of 75.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Last Earnings
3/17/2025
Today
10/20/2025
Fiscal Year End
7/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NYSE:ENZ
CIK
316253
Employees
520
Year Founded
1976

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.08 million
Net Margins
-75.34%
Pretax Margin
-23.79%
Return on Equity
-7.96%
Return on Assets
-5.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.55
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$29.09 million
Price / Sales
0.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
52,403,000
Free Float
46,288,000
Market Cap
$17.03 million
Optionable
Optionable
Beta
1.19

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:ENZ) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners